Chromosome 17 in fronto temporal lobak degeneration (FTLD): From MAPT to progranulin and back

Current Alzheimer Research

Volumn 8, Issue 3, 2011, Pages 229-236

  Alberici, A ^a   Cosseddu, M ^a   Padovani, A ^a   Borroni, B ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Fronto temporal lobak degeneration; Mapt; Progranulin

Indexed keywords

PROGRANULIN; TAR DNA BINDING PROTEIN; TAU PROTEIN; GRN PROTEIN, HUMAN; MAPT PROTEIN, HUMAN; SIGNAL PEPTIDE;

ARTICLE; AUTOPSY; BEHAVIOR DISORDER; CHROMOSOME 17; CLINICAL FEATURE; EXTRAPYRAMIDAL SYMPTOM; FRONTOTEMPORAL DEMENTIA; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; MONOGENIC DISORDER; MOTOR NEURON DISEASE; MUTATION; NEUROPATHOLOGY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN AGGREGATION; ANIMAL; GENETICS; REVIEW;

ANIMALS; CHROMOSOMES, HUMAN, PAIR 17; FRONTOTEMPORAL DEMENTIA; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; TAU PROTEINS;

EID: 79956258452     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720511795563737     Document Type: Article

References (93)

1. Pick A. Uber die Beziehungen der senilen Hirnatrophie zur Aphasie. Prager Med Wochenschr 17: 165-167 (1892).
2. Knopman DS, Mastri AR, Frey WH 2nd, Sung JH, Rustan T. Dementia lacking distinctive histologic features: a common non-Alzheimer degenerative dementia. Neurology 40: 251-256 (1990).
3. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurosurg Psychiatry 57(4): 416-418 (1994).
4. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: A consensus of clinical diagnostic criteria. Neurology 51(6): 1546-1554 (1998).
5. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47(1): 1-9 (1996).
6. Lang A. Cortical-basal ganglionic degeneration. In Saunders (Ed.), Neurodegenerative Dis 877-894 (1994).
7. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ. Clinical and Pathological Diagnosis of Frontotemporal Dementia. Report of the work group on frontotemporal dementia and Pick's disease. Arch Neurol 58: 1803-1809 (2001).
8. Kertesz A, McMonagle P, Blair M, Davidson W, Munoz DG. The evolution and pathology of frontotemporal dementia. Brain 128: 1996-2005 (2005).
9. Davies RR, Kipps CM, Mitchell J, Kril JJ, Halliday GM, Hodges JR. Progression in frontotemporal dementia: identifying a benign behavioral variant by magnetic resonance imaging. Arch Neurol 63(11): 1627-1631 (2006).
10. Borroni B, Grassi M, Agosti C, Premi E, Alberici A, Paghera B, et al. Survival in frontotemporal lobar degeneration and related disorders: latent class predictors and brain functional correlates. Rejuvenation Res 12(1): 33-44 (2009).
11. Hodges JR, Davies R, Xuereb J, Kril J, Halliday G. Survival in frontotemporal dementia. Neurology 61(3): 349-354 (2003).
12. Hodges JR, Mitchell J, Dawson K, Spillantini MG, Xuereb JH, McMonagle P, et al. Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. Brain 133: 300-306 (2010).
13. Kipps CM, Nestor PJ, Dawson CE, Mitchell J, Hodges JR. Measuring progression in frontotemporal dementia: implications for therapeutic interventions. Neurology 70(22): 2046-2052 (2008).
14. Knopman DS, Kramer JH, Boeve BF, Caselli RJ, Graff-Radford NR, Mendez MF, et al. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain 13: 2957-2968 (2008).
15. Johnson JK, Diehl J, Mendez MF, Neuhaus J, Shapira JS, Forman M, et al. Frontotemporal lobar degeneration: demographic characteristics of 353 patients. Arch Neurol 62(6): 925-930 (2005).
16. Mercy L, Hodges JR, Dawson K, Barker RA, Brayne C. Incidence of early-onset dementias in Cambridgeshire, United Kingdom. Neurology 71(19): 1496-9 (2008).
17. Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology 58(11): 1615-1621 (2002).
18. Rosso SM, Donker Kaat L, Baks T, Joosse M, de Koning I, Pijnenburg Y, et al. Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a populationbased study. Brain 126(Pt 9): 2016-2022 (2003).
19. Gislason TB, Sjögren M, Larsson L, Skoog I. The prevalence of frontal variant frontotemporal dementia and the frontal lobe syn-drome in a population based sample of 85 year olds. J Neurol Neurosurg Psychiatry 74(7): 867-871 (2003).
20. Borroni B, Alberici A, Grassi M, Turla M, Zanetti O, Bianchetti A, et al. Is Frontotemporal Lobar Degeneration a Rare Disorder? Evidence from a preliminary study in brescia county, Italy. J Alzheimers Dis 19(1): 111-116 (2010).
21. Gruntal E. Klinish-genealogischer Nachweis von Erblichkeit bei Pickscher Krankheit. Zeitschrift Fur gesante Neurologie Psychiatrie 136: 464 (1931).
22. Lowenberg K, Boyd DA, Salon DD. Occurrence of Pick's in early adult years. Arch Neurol Psychiat 41: 1004-1020 (1939).
23. Stevens M, van Duijn CM, Kamphorst W, de Knijff P, Heutink P, van Gool WA, et al. Familial aggregation in frontotemporal dementia. Neurology 50(6): 1541-1545 (1998).
24. Skibinski G, Parkinson NJ, Brown JM, Chakrabarti L, Lloyd SL, Hummerich H, et al. Mutations in the endosomal ESCRTIIIcomplex subunit CHMP2B in frontotemporal dementia. Nat Genet 37(8): 806-808 (2005).
25. Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosincontaining protein. Nat Genet 36(4): 377-381 (2004).
26. Hosler BA, Siddique T, Sapp PC, Sailor W, Huang MC, Hossain A, et al. Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. JAMA 284(13): 1664-1669 (2000).
27. Morita M, Al-Chalabi A, Andersen PM, Hosler B, Sapp P, Englund E, et al. A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology 66(6): 839-844 (2006).
28. Vance C, Al-Chalabi A, Ruddy D, Smith BN, Hu X, Sreedharan J, et al. Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. Brain 129(Pt 4): 868-876. (2006).
29. Foster NL, Wilhelmsen K, Sima AA, Jones MZ, D'Amato CJ, Gilman S. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference Participants. Ann Neurol 41(6): 706-715 (1997).
30. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 18:393(6686): 702-705 (1998).
31. Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442: 916-919 (2006).
32. Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442: 920-924 (2006).
33. Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 119: 1-4 (2010).
34. Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar HA, Mackenzie IR. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132(Pt 11): 2922-2931 (2009).
35. Urwin H, Josephs KA, Rohrer JD, Mackenzie IR, Neumann M, Authier A, et al. FUS pathology in basophilic inclusion body disease. Acta Neuropathol 120(1): 33-41 (2010).
36. Van Langenhove T, van der Zee J, Sleegers K, Engelborghs S, Vandenberghe R, Gijselinck I, et al. Genetic contribution of FUS to frontotemporal lobar degeneration. Neurology 74(5): 366-371 (2010).
37. Munoz DG, Neumann M, Kusaka H, Yokota O, Ishihara K, Terada S, et al. FUS pathology in basophilic inclusion body disease. Acta Neuropathol 118(5):617-27 (2009).
38. Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci U S A 85(11): 4051-4055 (1988).
39. Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J 8(2): 393-399 (1989).
40. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3(4): 519-526 (1989).
41. Matsuo ES, Shin RW, Billingsley ML, Van deVoorde A, O'Connor M, Trojanowski JQ, et al. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron 13(4): 989-1002 (1994).
42. Pastorino L, Sun A, Lu PJ, Zhou XZ, Balastik M, Finn G, et al. The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature 440(7083): 528-534 (2006).
43. Lu PJ, Wulf G, Zhou XZ, Davies P, Lu KP. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 399(6738): 784-788 (1999).
44. Dixit R, Ross JL, Goldman YE, Holzbaur EL. Differential regulation of dynein and kinesin motor proteins by tau. Science 319(5866): 1086-1089 (2008).
45. Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 156(6): 1051-1063 (2002).
46. Magnani E, Fan J, Gasparini L, Golding M, Williams M, Schiavo G, et al. Interaction of tau protein with the dynactin complex. EMBO J 26(21): 4546-4554 (2007).
47. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300(5619): 636-640 (2003).
48. Rizzu P, Hinkle DA, Zhukareva V, Bonifati V, Severijnen LA, Martinez D, et al. DJ-1 colocalizes with tau inclusions: a link between parkinsonism and dementia. Ann Neurol 55(1): 113-118 (2004).
49. Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet 13(7): 703-714 (2004).
50. Kaivorinne AL, Krüger J, Kuivaniemi K, Tuominen H, Moilanen V, Majamaa K, et al. Role of MAPT mutations and haplotype in frontotemporal lobar degeneration in Northern Finland. BMC Neurol 17: 8-48 (2008).
51. Dumanchin C, Camuzat A, Campion D, Verpillat P, Hannequin D, Dubois B, et al. Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism. Hum Mol Genet 7(11): 1825-1829 (1998).
52. Houlden H, Baker M, Adamson J, Grover A, Waring S, Dickson D, et al. Frequency of tau mutations in three series of non-Alzheimer's degenerative dementia. Ann Neurol 46(2): 243-248 (1999).
53. Morris HR, Khan MN, Janssen JC, Brown JM, Perez-Tur J, Baker M, et al. The genetic and pathological classification of familial frontotemporal dementia. Arch Neurol 58(11): 1813-1816 (2001).
54. Poorkaj P, Grossman M, Steinbart E, Payami H, Sadovnick A, Nochlin D, et al. Frequency of tau gene mutations in familial and sporadic cases of non-Alzheimer dementia. Arch Neurol 58(3): 383-387 (2001).
55. Rizzu P, Van Swieten JC, Joosse M, Hasegawa M, Stevens M, Tibben A, et al. High prevalence of mutations in the microtubuleassociated protein tau in a population study of frontotemporal dementia in the Netherlands. Am J Hum Genet 64 (2): 414-421 (1999).
56. Binetti G, Nicosia F, Benussi L, Ghidoni R, Feudatari E, Barbiero L, et al. Prevalence of TAU mutations in an Italian clinical series of familial frontotemporal patients. Neurosci Lett 338(1): 85-87 (2003).
57. Boeve BF, Hutton M. Refining frontotemporal dementia with parkinsonism linked to chromosome 17: introducing FTDP-17 (MAPT) and FTDP-17 (PGRN). Arch Neurol 65(4): 460-464 (2008).
58. Geschwind DH, Robidoux J, Alarcón M, Miller BL, Wilhelmsen KC, Cummings JL, et al. Dementia and neurodevelopmental predisposition: cognitive dysfunction in presymptomatic subjects precedes dementia by decades in frontotemporal dementia. Ann Neurol 50(6): 741-746 (2001).
59. Rohrer JD, Ridgway GR, Modat M, Ourselin S, Mead S, Fox NC, et al. Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations. Neuroimage 53(3): 1070-6 (2010).
60. Bian H, Van Swieten JC, Leight S, Massimo L, Wood E, Forman M, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 70(19 Pt 2): 1827-1835 (2008).
61. Goode BL, Chau M, Denis PE, Feinstein SC. Structural and functional differences between 3-repeat and 4-repeat tau isoforms. Implications for normal tau function and the onset of neurodegenetative disease. J Biol Chem 275(49): 38182-38189 (2000).
62. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 102(19): 6990-6995 (2005).
63. Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA 102(1): 227-231 (2005).
64. Rovelet-Lecrux A, Deramecourt V, Legallic S, Maurage CA, Le Ber I, Brice A, et al. Deletion of the progranulin gene in patients with frontotemporal lobar degeneration or Parkinson disease. Neurobiol Dis 31(1): 41-45 (2008).
65. Rovelet-Lecrux A, Lecourtois M, Thomas-Anterion C, Le Ber I, Brice A, Frebourg T, et al. Partial deletion of the MAPT gene: a novel mechanism of FTDP-17. Hum Mutat 30(4): 591-602 (2009).
66. Bhandari V, Palfree RG, Bateman A. Isolation and sequence of the granulin precursor cDNA from human bone marrow reveals tandem cysteine-rich granulin domains. Proc Natl Acad Sci USA 89(5): 1715-1719 (1992).
67. Baba T, Hoff HB 3rd, Nemoto H, Lee H, Orth J, Arai Y, et al. Acrogranin, an acrosomal cysteine-rich glycoprotein, is the precursor of the growth-modulating peptides, granulins, and epithelins, and is expressed in somatic as well as male germ cells. Mol Reprod Dev 34(3): 233-243 (1993).
68. Hrabal R, Chen Z, James S, Bennett HP, Ni F. The hairpin stack fold, a novel protein architecture for a new family of protein growth factors. Nat Struct Biol 3(9): 747-752 (1996).
69. Zhu J, Nathan C, Jin W, Sim D, Ashcroft GS, Wahl SM, et al. Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 111(6): 867-878 (2002).
70. He Z, Ong CH, Halper J, Bateman A. Progranulin is a mediator of the wound response. Nat Med 9(2): 225-229 (2003).
71. He Z, Bateman A. Progranulin gene expression regulates epithelial cell growth and promotes tumor growth in vivo. Cancer Res 59(13): 3222-3229 (1999).
72. Liau LM, Lallone RL, Seitz RS, Buznikov A, Gregg JP, Kornblum HI, et al. Identification of a human glioma-associated growth factor gene, granulin, using differential immuno-absorption. Cancer Res 60(5): 1353-1360 (2000).
73. Van Damme P, Van Hoecke A, Lambrechts D, Vanacker P, Bogaert E, van Swieten J, et al. Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol 181(1): 37-41 (2008).
74. van der Zee J, Le Ber I, Maurer-Stroh S, Engelborghs S, Gijselinck I, Camuzat A, et al. Mutations other than null mutations producing a pathogenic loss of progranulin in frontotemporal dementia. Hum Mutat 28(4): 416 (2007).
75. Gass J, Cannon A, Mackenzie IR, Boeve B, Baker M, Adamson J, et al. Mutations in progranulin are a major cause of ubiquitinpositive frontotemporal lobar degeneration. Hum Mol Genet 15(20): 2988-3001 (2006).
76. Le Ber I, van der Zee J, Hannequin D, Gijselinck I, Campion D, Puel M, et al. Progranulin null mutations in both sporadic and familial frontotemporal dementia. Hum Mutat 28(9): 846-855 (2007).
77. Borroni B, Archetti S, Alberici A, Agosti C, Gennarelli M, Bigni B, et al. Progranulin genetic variations in frontotemporal lobar degeneration: evidence for low mutation frequency in an Italian clinical series. Neurogenetics 9(3): 197-205 (2008).
78. Bruni AC, Momeni P, Bernardi L, Tomaino C, Frangipane F, Elder J, et al. Heterogeneity within a large kindred with frontotemporal dementia: a novel progranulin mutation. Neurology 69(2): 140-147 (2007).
79. Krüger J, Kaivorinne AL, Udd B, Majamaa K, Remes AM. Low prevalence of progranulin mutations in Finnish patients with frontotemporal lobar degeneration. Eur J Neurol 16(1): 27-30 (2009).
80. Guerreiro RJ, Santana I, Bras JM, Revesz T, Rebelo O, Ribeiro MH, et al. Novel progranulin mutation: screening for PGRN mutations in a Portuguese series of FTD/CBS cases. Mov Disord 23(9): 1269-1273 (2008).
81. Whitwell JL, Jack CR Jr, Baker M, Rademakers R, Adamson J, Boeve BF, et al. Voxel-based morphometry in frontotemporal lobar degeneration with ubiquitin-positive inclusions with and without progranulin mutations. Arch Neurol 64(3): 371-376 (2007).
82. Rohrer JD, Warren JD, Omar R, Mead S, Beck J, Revesz T, et al. Parietal lobe deficits in frontotemporal lobar degeneration caused by a mutation in the progranulin gene. Arch Neurol 65(4): 506-513 (2008).
83. Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology 71(16): 1235-1239 (2008).
84. Finch N, Baker M, Crook R, Swanson K, Kuntz K, Surtees R, et al. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain 132(Pt 3): 583-591 (2009).
85. Buratti E, Dörk T, Zuccato E, Pagani F, Romano M, Baralle FE. Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J 20(7): 1774-1784 (2001).
86. Buratti E, Baralle FE. Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. Front Biosci 13: 867-878 (2008).
87. Borroni B, Bonvicini C, Alberici A, Buratti E, Agosti C, Archetti S, et al. Mutation within TARDBP leads to frontotemporal dementia without motor neuron disease. Hum Mutat 30(11): 974-983 (2009).
88. Benajiba L, Le Ber I, Camuzat A, Lacoste M, Thomas-Anterion C, Couratier P, et al. TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann Neurol 65(4): 470-473 (2009).
89. Kovacs GG, Murrell JR, Horvath S, Haraszti L, Majtenyi K, Molnar MJ, et al. TARDBP variation associated with frontotemporal dementia, supranuclear gaze palsy, and chorea. Mov Disord 24(12): 1843-1847 (2009).
90. Zhang YJ, Xu YF, Dickey CA, Buratti E, Baralle F, Bailey R, et al. Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci 27(39): 10530-10534 (2007).
91. Moisse K, Volkening K, Leystra-Lantz C, Welch I, Hill T, Strong MJ. Divergent patterns of cytosolic TDP-43 and neuronal progranulin expression following axotomy: implications for TDP-43 in the physiological response to neuronal injury. Brain Res 1249: 202-211 (2009).
92. Alberici A, Gobbo C, Panzacchi A, Nicosia F, Ghidoni R, Benussi L, et al. Frontotemporal dementia: impact of P301L tau mutation on a healthy carrier. J Neurosurg Psychiatry 75: 1607-1610 (2004).
93. Borroni B, Alberici A, Premi E, Archetti S, Garibotto V, Agosti C, et al. Brain magnetic resonance imaging structural changes in a pedigree of asymptomatic progranulin mutation carriers. Rejuvenation Res 11(3): 585-595 (2008).